Philadelphia (February 24, 2016) – Oncoceutics, Inc. announced that a new U.S. patent #9,265,765 has been awarded for composition of matter protection for the disalt form of ONC201 under clinical development as the company’s lead compound. The patent also covers the use of any preparation of ONC201 with any other therapeutic agent for use in both cancer and other indications.
Two other U.S. patents for the lead product were issued over the course of 2015. U.S. patent #9,072,744 was issued for the use of the lead compound in colon cancer, breast cancer, lymphoma, and non-small cell lung cancer as a single agent and in combination with select anticancer drugs. U.S. patent # 9,061,032 was also issued for the use of ONC201 in lung or breast cancer in combination with mitotic inhibitors.
Oncoceutics previously announced the issuance of U.S. patent #8,673,923 for the use of ONC201 in patients with brain cancer as a single agent or in combination with select anticancer drugs.
Collectively, this portfolio of issued patents provides a multi-pronged and robust protection of Oncoceutics’ lead compound ONC201 that continues to be expanded by ongoing prosecution in the US and elsewhere. These patent claims and others are under prosecution in all other major global markets.
“We are delighted to have been awarded a U.S. Patent for the salt form of our lead molecule ONC201,” said Martin Stogniew, PhD, Chief Development Officer at Oncoceutics. “During our characterization of the original molecule, we uncovered several unexpected findings and major improvements, allowing us to create a unique IP portfolio around ONC201. The latest addition to our patent family provides a long coverage for this new molecule that is already in Phase II clinical development and represents a critical achievement to translate this drug into a commercially viable asset.”
Oncoceutics, Inc. is a clinical-stage drug discovery and development company targeting potent suppressor pathways in human cancer. The first lead compound that entered clinical development from this program is ONC201, a small molecule with an active angular structure and a first-in-class mechanism of action that causes significant anti-tumor activity in a variety of human cancers. The company recently completed a successful Phase I study in solid tumors and has begun Phase II clinical programs in both solid and hematological malignancies. Oncoceutics has been awarded several competitive grants for its development programs with ONC201 and its other candidates in this new class of compounds. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements between Oncoceutics and leading comprehensive cancer centers, including The University of Texas MD Anderson Cancer Center and the Fox Chase Cancer Center. The company has established a robust Intellectual property position, including several issued patents.